Outlook Therapeutics Completes FDA Appeal Meeting for ONS-5010 BLA; Decision Expected in May

summarizeSummary

Outlook Therapeutics announced it completed a Federal Dispute Resolution meeting with the FDA to appeal the Complete Response Letter for its wet AMD treatment, ONS-5010, with a formal decision expected in May 2026.

check_boxKey Events

• FDA Appeal Meeting Completed

  Outlook Therapeutics announced it has completed the Federal Dispute Resolution (FDR) meeting with the FDA regarding the appeal of the Complete Response Letter (CRL) for ONS-5010.

• Regulatory Status Update

  The meeting addressed the December 30, 2025 CRL for the Biologics License Application (BLA) resubmission for ONS-5010, an investigational treatment for wet AMD.

• Formal Decision Expected in May

  The company anticipates receiving formal feedback from the FDA in May 2026, which will determine the next steps for ONS-5010's potential U.S. approval.

auto_awesomeAnalysis

This 8-K provides a critical update on Outlook Therapeutics' regulatory pathway for ONS-5010, their investigational wet AMD treatment. The company previously received a Complete Response Letter (CRL) from the FDA in December 2025, which was a significant setback. The completion of this Federal Dispute Resolution meeting is a necessary procedural step in appealing that CRL. Given the company's previously disclosed "going concern" issues, the successful resolution of the ONS-5010 BLA is paramount for its future viability. Investors should monitor for the formal FDA feedback expected in May 2026, as this will be a major catalyst for the stock.